Oncology | Phase I/ Phase II Developments | NORWAY

Targovax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Targovax Announces That Abstract on Interim Phase I Clinical Data From the Phase I/II Peritoneal Trial is Accepted at ASCO

Lead Product(s): ONCOS-102,Durvalumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 06, 2020

Details:

Interim phase I data from the Phase I / II study of systemic durvalumab + intraperitoneal ONCOS-102 in peritoneal disease from ovarian or colorectal cancer will be presented at the ASCO20 conference.

Targovax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Targovax Releases Update for Mesothelioma Trial Combining ONCOS-102 and Chemotherapy

Lead Product(s): ONCOS-102,Cisplatin,Pemetrexed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2020

Details:

The updated PFS data demonstrate enhanced immune activation and modulation of tumor microenvironment in ONCOS-102-treated patients compared to the control group.

Targovax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Targovax Announces Encouraging Data in Mesothelioma Study Combining ONCOS-102 and Standard of Care Chemotherapy

Lead Product(s): ONCOS-102,Cisplatin,Pemetrexed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2020

Details:

Preliminary data show a numerical advantage in Progression Free Survival in ONCOS-102 treated patients.

Targovax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Targovax and IOVaxis Therapeutics Enters Option Agreement for TG Mutant RAS Vaccine License and Clinical Development in China

Lead Product(s): Apricoxib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: IOVaxis Therapeutics

Deal Size: $100.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 08, 2020

Details:

Under the agreement, IOVaxis and Targovax will jointly define a development plan in the territory, and IOVaxis will be responsible for all local regulatory filings and will sponsor clinical trials.

Find

Find Oncology Drugs in Phase I/II Clinical Development in NORWAY

Norway

Product Type

Companies

Targovax

Targovax Announces That Abstract on Interim Phase I Clinical Data From the Phase I/II Peritoneal Trial is Accepted at ASCO

Targovax

Targovax Releases Update for Mesothelioma Trial Combining ONCOS-102 and Chemotherapy

Targovax

Targovax Announces Encouraging Data in Mesothelioma Study Combining ONCOS-102 and Standard of Care Chemotherapy

Targovax

Targovax and IOVaxis Therapeutics Enters Option Agreement for TG Mutant RAS Vaccine License and Clinical Development in China